KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Deferred Taxes: 2022-2025

Historic Deferred Taxes for Neogenomics (NEO) over the last 4 years, with Sep 2025 value amounting to -$869,000.

  • Neogenomics' Deferred Taxes fell 456.15% to -$869,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 33.24%. This contributed to the annual value of $3.1 million for FY2024, which is 72.57% down from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Deferred Taxes is -$869,000, which was down 187.51% from $993,000 recorded in Q2 2025.
  • Neogenomics' Deferred Taxes' 5-year high stood at $5.7 million during Q2 2022, with a 5-year trough of -$869,000 in Q3 2025.
  • Its 3-year average for Deferred Taxes is $1.4 million, with a median of $993,000 in 2025.
  • Data for Neogenomics' Deferred Taxes shows a peak YoY increase of 109.05% (in 2025) and a maximum YoY decrease of 456.15% (in 2025) over the last 5 years.
  • Neogenomics' Deferred Taxes (Quarterly) stood at $3.3 million in 2022, then plummeted by 45.34% to $1.8 million in 2023, then dropped by 14.18% to $1.6 million in 2024, then crashed by 456.15% to -$869,000 in 2025.
  • Its Deferred Taxes stands at -$869,000 for Q3 2025, versus $993,000 for Q2 2025 and $541,000 for Q1 2025.